Importer of Controlled Substances; Notice of Application, 53605-53606 [E7-18497]

Download as PDF 53605 rwilkins on PROD1PC63 with NOTICES Federal Register / Vol. 72, No. 181 / Wednesday, September 19, 2007 / Notices Industries (202–205–3349 or eric.land@usitc.gov). For more information on legal aspects of the investigation, contact William Gearhart of the Commission’s Office of the General Counsel (202–205–3091 or william.gearhart@usitc.gov). The media should contact Margaret O’Laughlin, Office of External Relations (202–205– 1819 or margaret.olaughlin@usitc.gov). Hearing-impaired individuals may obtain information on this matter by contacting the Commission’s TDD terminal at 202–205–1810. General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS–ONLINE) at http://www.usitc.gov/secretary/ edis.htm. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. Background: As requested by the USTR, in accordance with section 503(a)(1)(A), 503(e), and 131(a) of the Trade Act of 1974, as amended (19 U.S.C. 2463(a)(1)(A), 19 U.S.C. 2151(a)), and pursuant to section 332(g) of the Tariff Act of 1930 (19 U.S.C. 1332(g)), the Commission will provide advice as to the probable economic effect on U.S. industries producing like or directly competitive articles and on consumers of the elimination of U.S. import duties for all beneficiary developing countries under the GSP program on articles provided for in HTS subheadings 2613.10.00, 2613.90.00, 2917.12.10, 3204.17.90, 4412.39.5030, 7601.10.30, 7601.20.30, 7604.21.00, and 8111.00.4910. Also, as requested by USTR, pursuant to section 332(g) of the Tariff Act of 1930, the Commission will provide advice as to the probable economic effect on U.S. industries producing like or directly competitive articles and on consumers of the removal from eligibility for duty-free treatment under the GSP program of articles provided for in HTS subheadings 2931.00.90 from India and 3920.62.00 from Brazil. As requested by the USTR, the Commission will provide its advice no later than December 19, 2007. The USTR indicated that those sections of the Commission’s report and related working papers that contain the Commission’s advice will be classified as ‘‘confidential.’’ Public Hearing: A public hearing in connection with this investigation will be held beginning at 9:30 a.m. on October 16, 2007 at the United States International Trade Commission Building, 500 E Street SW., Washington, VerDate Aug<31>2005 17:49 Sep 18, 2007 Jkt 211001 DC. All persons have the right to appear by counsel or in person, to present information, and to be heard. Persons wishing to appear at the public hearing should file a letter with the Secretary, United States International Trade Commission, 500 E St., SW., Washington, DC 20436, not later than the close of business (5:15 p.m.) on September 25, 2007, in accordance with the requirements in the ‘‘Submissions’’ section below. Written Submissions: In lieu of or in addition to participating in the hearing, interested parties are invited to submit written statements or briefs concerning these investigations. All written submissions, including requests to appear at the hearing, statements, and briefs, should be addressed to the Secretary, United States International Trade Commission, 500 E Street, SW., Washington, DC 20436. Pre-hearing briefs and statements should be filed not later than 5:15 p.m., September 26, 2007; and post-hearing briefs and statements and all other written submissions should be filed not later than 5:15 p.m., October 24, 2007. All written submissions must conform with the provisions of section 201.8 of the Commission’s Rules of Practice and Procedure (19 CFR 201.8). Section 201.8 of the rules requires that a signed original (or a copy designated as an original) and fourteen (14) copies of each document be filed. In the event that confidential treatment of the document is requested, at least four (4) additional copies must be filed, in which the confidential information must be deleted (see the following paragraph for further information regarding confidential business information). The Commission’s rules do not authorize filing submissions with the Secretary by facsimile or electronic means, except to the extent permitted by section 201.8 of the rules (see Handbook for Electronic Filing Procedures, http:// www.usitc.gov/secretary/ fed_reg_notices/rules/documents/ handbook_on_electronic_filing.pdf). Persons with questions regarding electronic filing should contact the Secretary (202–205–2000). Any submissions that contain confidential business information must also conform with the requirements of section 201.6 of the Commission’s Rules of Practice and Procedure (19 CFR 201.6). Section 201.6 of the rules requires that the cover of the document and the individual pages be clearly marked as to whether they are the ‘‘confidential’’ or ‘‘nonconfidential’’ version, and that the confidential business information be clearly identified by means of brackets. All PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 written submissions, except for confidential business information, will be made available in the Office of the Secretary to the Commission for inspection by interested parties. The Commission may include some or all of the confidential business information submitted in the course of these investigations in the report it sends to the USTR. As requested by the USTR, the Commission will publish a public version of the report, which will exclude portions of the report that the USTR has classified as confidential as well as any confidential business information. Issued: September 12, 2007. By order of the Commission. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E7–18408 Filed 9–18–07; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on October 10, 2006, Lannett Company Incorporated, 9001 Torresdale Avenue, Philadelphia, Pennsylvania 19136, made application by letter and subsequent renewal on February 19, 2007 to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances: Drug Tetrahydrocannabinols (7370) ..... Methylphenidate (1724) ................ Morphine (9300) ........................... Schedule I II II The company plans to import the basic classes of controlled substances for analytical testing on a formulated product for submission to U.S. Food and Drug Administration (FDA) for generic product approval. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of E:\FR\FM\19SEN1.SGM 19SEN1 53606 Federal Register / Vol. 72, No. 181 / Wednesday, September 19, 2007 / Notices controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia 22301; and must be filed no later than October 19, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–43746), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: September 12, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–18497 Filed 9–18–07; 8:45 am] BILLING CODE 4410–09–P Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by NIDA. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than November 19, 2007. Dated: September 12, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–18446 Filed 9–18–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Occupational Safety and Health Administration [Docket No. OSHA–2007–0064] Federal Advisory Council on Occupational Safety and Health (FACOSH): Announcement of Meeting Occupational Safety and Health Administration (OSHA), Labor. ACTION: Announcement of meeting. AGENCY: DEPARTMENT OF JUSTICE Drug Enforcement Administration rwilkins on PROD1PC63 with NOTICES Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 24, 2007, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, P.O. Box 12194, East Institute Drive, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: VerDate Aug<31>2005 16:58 Sep 18, 2007 Jkt 211001 SUMMARY: The Federal Advisory Council on Occupational Safety and Health (FACOSH) will meet October 11, 2007, in Washington, DC. DATES: FACOSH meeting: FACOSH will meet from 1 p.m. to 4:30 p.m., Thursday, October 11, 2007. Submission of comments and requests to speak: Comments and requests to speak at the FACOSH meeting must be received by October 4, 2007. ADDRESSES: FACOSH meeting: FACOSH will meet in Room C–5521, Conference Room 4, U.S. Department of Labor, 200 Constitution Avenue, NW., Washington, DC 20210. PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 Submission of comments and requests to speak: Comments and requests to speak at the FACOSH meeting, identified by OSHA Docket No. 2007– 0064, may be submitted by any of the following methods: Electronically: You may submit materials, including attachments, electronically at: http:// www.regulations.gov, the Federal eRulemaking Portal. Follow the online instructions for making submissions. Facsimile: If your submission, including attachments, is not longer than 10 pages, you may fax it to the OSHA Docket Office at (202) 693–1648. Mail, express delivery, hand delivery, messenger or courier service: Submit three copies of your submissions to the OSHA Docket Office, Room N–2625, U.S. Department of Labor, 200 Constitution Avenue, NW., Washington, DC 20210; telephone (202) 693–2350 (OSHA’s TTY number is (877) 889– 5627). Deliveries (hand, express mail, messenger and courier service) are accepted during the Department of Labor’s and OSHA Docket Office’s normal business hours, 8:15 a.m.–4:45 p.m., e.t. Instructions: All submissions must include the Agency name and docket number for this Federal Register notice (Docket No. OSHA–2007–0064). Submissions in response to this Federal Register notice, including personal information provided, will be posted without change at: http:// www.regulations.gov. Therefore, OSHA cautions interested parties about submitting personal information such as social security numbers and birth dates. Because of security-related procedures, submissions by regular mail may result in a significant delay in their receipt. Please contact the OSHA Docket Office, at the address above, for information about security procedures for making submissions by hand delivery, express delivery, and messenger or courier service. For additional information on submitting comments and requests to speak, see the SUPPLEMENTARY INFORMATION section below. Docket: To read or download submissions, go to http:// www.regulations.gov. All documents in the docket are listed in the http:// www.regulations.gov index. Although listed in the index, some documents (e.g., copyrighted material) are not publicly available to read or download through http://www.regulations.gov. All submissions, including copyrighted material, are available for inspection and copying at the OSHA Docket Office at the address above. FOR FURTHER INFORMATION CONTACT: For general information: Diane Brayden, E:\FR\FM\19SEN1.SGM 19SEN1

Agencies

[Federal Register Volume 72, Number 181 (Wednesday, September 19, 2007)]
[Notices]
[Pages 53605-53606]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-18497]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952(a) authorizing the importation of such 
substances, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on October 10, 2006, Lannett Company Incorporated, 9001 Torresdale 
Avenue, Philadelphia, Pennsylvania 19136, made application by letter 
and subsequent renewal on February 19, 2007 to the Drug Enforcement 
Administration (DEA) for registration as an importer of the basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Methylphenidate (1724).....................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to import the basic classes of controlled 
substances for analytical testing on a formulated product for 
submission to U.S. Food and Drug Administration (FDA) for generic 
product approval.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic classes of

[[Page 53606]]

controlled substances may file comments or objections to the issuance 
of the proposed registration and may, at the same time, file a written 
request for a hearing on such application pursuant to 21 CFR 1301.43 
and in such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC 20537, or any being sent via express mail should be sent 
to Drug Enforcement Administration, Office of Diversion Control, 
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than October 19, 
2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-43746), all applicants for 
registration to import a basic class of any controlled substances in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), 
(c), (d), (e), and (f) are satisfied.

     Dated: September 12, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-18497 Filed 9-18-07; 8:45 am]
BILLING CODE 4410-09-P